Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1263 is a short (20–24 nucleotide) non-coding RNA molecule, part of a class of microRNAs that regulate gene expression mainly by destabilizing or inhibiting translation of target mRNAs[2]. It is transcribed from the human genome as part of a longer precursor molecule, which is processed by Drosha and Dicer enzymes to yield the mature form[2]. miR-1263 has been identified as highly enriched in definitive endoderm cells during differentiation of human embryonic stem cells and is a critical regulator promoting endoderm cell fate through repression of key pluripotency factors such as KLF4[1]. Its role in disease is not currently defined, and it is not known to be directly targeted by therapeutic agents or used as a clinical biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 1263 (miR-1263).